Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was down 4.2% on Friday . The stock traded as low as $10.25 and last traded at $10.63, with a volume of 639,769 shares traded. The stock had previously closed at $11.10.

Several analysts have recently commented on KPTI shares. Leerink Swann reaffirmed a “buy” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, May 10th. Raymond James Financial Inc. started coverage on Karyopharm Therapeutics in a research report on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price for the company. Jefferies Group cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 target price for the company. in a research report on Wednesday, June 1st. Wedbush reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, June 10th. Finally, Robert W. Baird started coverage on Karyopharm Therapeutics in a research report on Monday, June 27th. They issued an “outperform” rating and a $16.00 target price for the company. Two research analysts have rated the stock with a sell rating and eleven have issued a buy rating to the stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.97.

The company’s market cap is $382.20 million. The firm’s 50-day moving average is $7.46 and its 200-day moving average is $7.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.08. Equities research analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 45,541 shares of the business’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $9.21, for a total transaction of $419,432.61. Following the sale, the insider now directly owns 8,605,818 shares of the company’s stock, valued at approximately $79,259,583.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.